Search results for Figitumumab

Figitumumab Biosimilar – Anti-IGF1R, CD221 mAb – Research Grade, ProteoGenix, PX-TA1208

Description of Figitumumab Biosimilar - Anti-IGF1R, CD221 mAb - Research Grade Introduction Figitumumab Biosimilar, also known as Anti-IGF1R, CD221 mAb, is a monoclonal antibody that targets the insulin-like growth factor 1 receptor (IGF1R) and is used for research purposes. This biosimilar is designed to mimic the activity of the original Figitumumab antibody, which was developed as a potential cancer therapy. In this article, we will discuss the structure, activity, and potential applications of Figitumumab Biosimilar. Structure of Figitumumab Biosimilar Figitumumab Biosimilar is a recombinant humanized monoclonal antibody that is produced in a laboratory using genetic engineering techniques. It is composed of two heavy chains and two light chains, each with a specific amino acid sequence. The antibody has a molecular weight of approximately 150 kDa. The heavy chains of Figitumumab Biosimilar consist of four constant regions (Fc) and one variable region (VH), while the light chains have two constant regions (CL) and one variable region (VL). The variable regions are responsible for binding to the IGF1R receptor, while the constant regions determine the antibody’s effector functions. Activity of Figitumumab Biosimilar Figitumumab Biosimilar binds to the IGF1R receptor, which is a transmembrane protein found on the surface of cells. This receptor plays a crucial role in cell proliferation, survival, and differentiation. When IGF1R is activated by its ligands, it triggers a signaling cascade that promotes cell growth and survival. By binding to IGF1R, Figitumumab Biosimilar blocks the activation of the receptor and inhibits the downstream signaling pathway. This leads to a decrease in cell growth and survival, making it a potential anti- cancer agent. Additionally, Figitumumab Biosimilar can also induce antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) to kill cancer cells. Potential Applications of Figitumumab Biosimilar Figitumumab Biosimilar has been primarily studied for its potential as a cancer therapy. It has shown promising results in preclinical studies and has been evaluated in clinical trials for various types of cancer, including lung, breast, and prostate cancer. However, due to the limited efficacy and safety concerns, the development of the original Figitumumab antibody was discontinued. The biosimilar version of Figitumumab can be used in research to study the role of IGF1R in cancer and other diseases. It can also be used as a tool to assess the efficacy and safety of potential IGF1R-targeted therapies. Furthermore, Figitumumab Biosimilar can also be used as a reference standard for quality control and bioassays in the development of other biosimilar antibodies. Conclusion In summary, Figitumumab Biosimilar is a recombinant humanized monoclonal antibody that targets the IGF1R receptor. It has a similar structure and activity to the original Figitumumab antibody and has shown potential in cancer therapy. However, further research is needed to fully understand its efficacy and safety. Figitumumab Biosimilar also has potential applications in research and as a reference standard for biosimilar development.

Figitumumab, Abbexa, abx831165

Figitumumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting IGF1R/CD221, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Figitumumab has been used in trials studying the treatment of Sarcoma, Solid Tumor, Breast Cancer, Lung Neoplasms, and Advanced Cancer, among others.

Figitumumab ELISA Kit, Abbexa, abx395048

Figitumumab ELISA Kit is a quantitative ELISA kit for detection of Figitumumab.Figitumumab is a fully humanized IgG2 mAb against IGF-1R. Its recommended dose is 20 mg/kg repeated weekly. In phase I trials treatment-related toxicities were generally mild. The most common adverse events reported were hyperglycemia, anorexia, nausea, elevation of liver function tests, diarrhea, hyperuracemia and fatigue. Figitumumab had shown significant activity against non-small-cell lung cancer (NSCLC) and it was planned to be evaluated in combination with chemotherapy in a randomized phase III trial in patients with metastatic NSCLC. However, the study was early discontinued on December 2009 because an independent monitoring committee concluded that the combination of figitumumab plus chemotherapy would be unlikely to meet the primary endpoint of improving overall survival compared to chemotherapy alone. Additionally, there were also some concerns that hyperglycemia could be a potential contributor of increased patients’ morbidity. In regard to breast cancer, figitumumab was planned to be tested in phase I trials as neo-adjuvant treatment, but the trial was withdrawn prior initiation, although there are preclinical data showing a additive and/or synergistic effect of figitumumab with chemotherapy in basal breast cancer subtype.

Figitumumab ELISA Kit, ProteoGenix, KPTX159

Description of Figitumumab ELISA Kit Introduction The Figitumumab ELISA Kit is a highly sensitive and specific assay used for the detection and quantification of Figitumumab, a monoclonal antibody that targets the insulin-like growth factor 1 receptor (IGF-1R). This kit is designed for use in various biological samples, including serum, plasma, and cell culture supernatants. The development of this ELISA kit has greatly aided in the research and development of Figitumumab as a potential therapeutic agent for various diseases. Structure of Figitumumab Figitumumab is a fully human monoclonal antibody with a molecular weight of approximately 150 kDa. It is composed of two heavy chains and two light chains, each containing a variable region and a constant region. The variable region of Figitumumab is responsible for its high specificity and affinity for the IGF-1R. The IGF-1R is a transmembrane receptor that plays a crucial role in cell growth and survival. It is a tyrosine kinase receptor, meaning it can activate various signaling pathways upon binding to its ligands, insulin-like growth factor 1 (IGF-1) and insulin-like growth factor 2 (IGF-2). Figitumumab specifically targets the extracellular domain of the IGF-1R, preventing the binding of IGF-1 and IGF-2 and inhibiting downstream signaling pathways. Activity of Figitumumab The main activity of Figitumumab is its ability to block the activation of the IGF-1R and inhibit downstream signaling pathways. This leads to the inhibition of cell growth and survival, making Figitumumab a potential therapeutic agent for various diseases characterized by abnormal cell growth, such as cancer. Research has shown that Figitumumab can induce cell cycle arrest and apoptosis in cancer cells that overexpress the IGF-1R. It has also been shown to enhance the effects of chemotherapy and radiation therapy in cancer treatment. In addition, Figitumumab has shown promising results in preclinical studies for the treatment of other diseases, such as type 2 diabetes and acromegaly. Application of Figitumumab ELISA Kit The Figitumumab ELISA Kit is a valuable tool for the detection and quantification of Figitumumab in biological samples. It is widely used in research and clinical studies to monitor Figitumumab levels in patients receiving treatment with this antibody. The kit can also be used to assess the pharmacokinetics of Figitumumab, allowing researchers to determine the optimal dosage and dosing schedule for maximum efficacy. In addition, the Figitumumab ELISA Kit can be used to screen for potential biomarkers that may predict the response to Figitumumab treatment. This can aid in patient selection and personalized treatment strategies for improved outcomes. Conclusion The Figitumumab ELISA Kit is a powerful tool for the detection and quantification of Figitumumab, a monoclonal antibody that targets the IGF-1R. Its high sensitivity and specificity make it an essential assay for the development and evaluation of Figitumumab as a potential therapeutic agent for various diseases. With its wide range of applications, the Figitumumab ELISA Kit continues to play a crucial role in advancing research and improving patient outcomes.

Figitumumab Biosimilar - Research Grade, ichor.bio, ICH5154

Detects human IGF1R

Research Grade Figitumumab (HY353056), abinScience, HY353056